Enzymatica: ColdZyme reduces viral load - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Enzymatica: ColdZyme reduces viral load - Redeye

{newsItem.title}

Redeye comments on the new study showing that ColdZyme reduces viral load by more than 99% when applied onto human cells infected with influenza A. We argue the results are positive from a marketing perspective as well as it reduces the questions regarding ColdZyme’s effect. We reiterate our base case of SEK6.5.

Länk till analysen i sin helhet: https://www.redeye.se/research/936172/enzymatica-coldzyme-reduces-viral-load?utm_source=finwire&utm_medium=RSS

Nyheter om Enzymatica

Läses av andra just nu

Om aktien Enzymatica

Senaste nytt